AstraZeneca ( (GB:AZN) ) has shared an announcement.
AstraZeneca PLC announced that as of 28 February 2025, its issued share capital with voting rights consists of 1,550,607,175 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
YTD Price Performance: 15.99%
Average Trading Volume: 2,726,207
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £185.6B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.